-
Mashup Score: 0Pegozafermin lowers high triglycerides, non-HDL and ApoB vs. placebo in small trial - 11 month(s) ago
Pegozafermin, a fibroblast growth factor 21 analog, reduced atherogenic particles in patients with severe hypertriglyceridemia and improved liver fat and insulin resistance compared with placebo, a speaker reported. Michael Miller, MD, FACC, FAHA, chief of medicine at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia and vice chair of medicine at the University of
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Black patients who undergo coronary artery calcium scoring received less post-screening care and had more adverse CV events compared with white patients at a single center, a speaker reported.The results of the retrospective IMPACT study were presented at the National Lipid Association Scientific Sessions.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: "The study, I hope, will help enable cardiovascular clinicians to better understand the racial disparities and help us improve the equitable access to care and minimize adverse events" @nationallipid #NLA2023 @uofl #cardiotwitter https://t.co/kPm3VzFd8w
-
-
Mashup Score: 0
Black patients who undergo coronary artery calcium scoring received less post-screening care and had more adverse CV events compared with white patients at a single center, a speaker reported.The results of the retrospective IMPACT study were presented at the National Lipid Association Scientific Sessions.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: "The study, I hope, will help enable cardiovascular clinicians to better understand the racial disparities and help us improve the equitable access to care and minimize adverse events" @nationallipid #NLA2023 @uofl #cardiotwitter https://t.co/kPm3VzFd8w
-
-
Mashup Score: 0Pegozafermin lowers high triglycerides, non-HDL and ApoB vs. placebo in small trial - 11 month(s) ago
Pegozafermin, a fibroblast growth factor 21 analog, reduced atherogenic particles in patients with severe hypertriglyceridemia and improved liver fat and insulin resistance compared with placebo, a speaker reported. Michael Miller, MD, FACC, FAHA, chief of medicine at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia and vice chair of medicine at the University of
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “Pegozafermin significantly reduced atherogenic particles across the board. That’s non-HDL cholesterol, ApoB, triglycerides, ApoC3 and liver fat in subjects with severe hypertriglyceridemia,” @mmillermd1 @nationallipid #NLA2023 #cardiotwitter https://t.co/qrbJ3PfnPn
-
-
Mashup Score: 0
Black patients who undergo coronary artery calcium scoring received less post-screening care and had more adverse CV events compared with white patients at a single center, a speaker reported.The results of the retrospective IMPACT study were presented at the National Lipid Association Scientific Sessions.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Black patients who undergo coronary artery calcium scoring received less post-screening care and had more adverse CV events compared with white patients at a single center, a speaker reported @nationallipid #NLA2023 @uofl #cardiotwitter https://t.co/kPm3VzFd8w
-
-
Mashup Score: 4Pegozafermin lowers high triglycerides, non-HDL and ApoB vs. placebo in small trial - 11 month(s) ago
Pegozafermin, a fibroblast growth factor 21 analog, reduced atherogenic particles in patients with severe hypertriglyceridemia and improved liver fat and insulin resistance compared with placebo, a speaker reported. Michael Miller, MD, FACC, FAHA, chief of medicine at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia and vice chair of medicine at the University of
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Pegozafermin, a fibroblast growth factor 21 analog, reduced atherogenic particles in patients with severe hypertriglyceridemia and improved liver fat and insulin resistance vs. placebo @mmillermd1 @PennMedNews @nationallipid #NLA2023 #cardiotwitter https://t.co/qrbJ3PfnPn
-
-
Mashup Score: 1
Targeted nutrition interventions can mitigate atherosclerotic CVD risk for people with the three most common dyslipidemias, and adherence can be encouraged via shared decision-making, according to a speaker.“The nutrition interventions … are meant to be implemented with the foundation of a multi-dietary pattern,” Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA, clinical scientist at
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: "The dietary portfolio approach, a combined effect of plant sterols, soy proteins and viscous fibers, may be as effective as the starting dose of older first-line drugs in managing hypercholesterolemia" #NLA2023 @carolkirkpat3 #cardiotwitter https://t.co/OA3tkN9dBZ
-
-
Mashup Score: 0
Targeted nutrition interventions can mitigate atherosclerotic CVD risk for people with the three most common dyslipidemias, and adherence can be encouraged via shared decision-making, according to a speaker.“The nutrition interventions … are meant to be implemented with the foundation of a multi-dietary pattern,” Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA, clinical scientist at
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: "The dietary portfolio approach, a combined effect of plant sterols, soy proteins and viscous fibers, may be as effective as the starting dose of older first-line drugs in managing hypercholesterolemia" #NLA2023 @carolkirkpat3 #cardiotwitter https://t.co/OA3tkN9dBZ
-
-
Mashup Score: 0
Targeted nutrition interventions can mitigate atherosclerotic CVD risk for people with the three most common dyslipidemias, and adherence can be encouraged via shared decision-making, according to a speaker.“The nutrition interventions … are meant to be implemented with the foundation of a multi-dietary pattern,” Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA, clinical scientist at
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Targeted nutrition interventions can mitigate atherosclerotic CVD risk for people with the three most common dyslipidemias, and adherence can be encouraged via shared decision-making @nationallipid #NLA2023 @carolkirkpat3 @ISUHealthSci #cardiotwitter https://t.co/OA3tkN9dBZ
-
-
Mashup Score: 1ROSE2: Obicetrapib/ezetimibe combination further lowers LDL in statin-treated patients - 11 month(s) ago
In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial. As Healio previously reported, obicetrapib (NewAmsterdam Pharma), an investigational cholesteryl ester transfer protein (CETP) inhibitor, decreased LDL, non-HDL, lipoprotein(a) and apolipoprotein B and increased HDL at 8 weeks in
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “With this data, we are moving forward with a fixed-dose combination tablet ... and we will initiate phase 3 in early 2024,” @nationallipid @LipidJournal @mdavidsonmd #cardiotwitter #NLA2023 https://t.co/iZu8LjPQlf
-
ICYMI: “Pegozafermin significantly reduced atherogenic particles across the board. That’s non-HDL cholesterol, ApoB, triglycerides, ApoC3 and liver fat in subjects with severe hypertriglyceridemia,” @mmillermd1 @nationallipid #NLA2023 #cardiotwitter https://t.co/qrbJ3PfnPn